Kirk Allen Coleman Net Worth

The estimated Net Worth of Kirk Allen Coleman is at least $456 Thousand dollars as of 15 August 2023. Mr Coleman owns over 20,000 units of Tff Pharmaceuticals Inc stock worth over $77,415 and over the last 5 years he sold TFFP stock worth over $0. In addition, he makes $378,500 as CFO and Treasurer & Sec. at Tff Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr Coleman TFFP stock SEC Form 4 insiders trading

Mr has made over 10 trades of the Tff Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of TFFP stock worth $5,000 on 15 August 2023.

The largest trade he's ever made was buying 20,000 units of Tff Pharmaceuticals Inc stock on 15 August 2023 worth over $5,000. On average, Mr trades about 4,730 units every 87 days since 2019. As of 15 August 2023 he still owns at least 35,675 units of Tff Pharmaceuticals Inc stock.

You can see the complete history of Mr Coleman stock trades at the bottom of the page.

Mr. Kirk Allen Coleman biography

Kirk Allen Coleman is the CFO, Treasurer & Sec. at Tff Pharmaceuticals Inc.

What is the salary of Mr Coleman?

As the CFO and Treasurer & Sec. of Tff Pharmaceuticals Inc, the total compensation of Mr Coleman at Tff Pharmaceuticals Inc is $378,500. There are 1 executives at Tff Pharmaceuticals Inc getting paid more, with Glenn R. Mattes having the highest compensation of $654,167.

How old is Mr Coleman?

Mr Coleman is 47, he's been the CFO and Treasurer & Sec. of Tff Pharmaceuticals Inc since . There are 4 older and no younger executives at Tff Pharmaceuticals Inc. The oldest executive at Tff Pharmaceuticals Inc is Glenn R. Mattes, 66, who is the Pres, CEO & Director.

What's Mr Coleman's mailing address?

Kirk's mailing address filed with the SEC is 1751 RIVER RUN, SUITE 400, , FORT WORTH, TX, 76107.

Insiders trading at Tff Pharmaceuticals Inc

Over the last 5 years, insiders at Tff Pharmaceuticals Inc have traded over $27,239,579 worth of Tff Pharmaceuticals Inc stock and bought 1,894,491 units worth $5,305,961 . The most active insiders traders include Therapeutics, Inc. Lung, Aaron G.L. Fletcher, and Harlan F Weisman. On average, Tff Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $174,967. The most recent stock trade was executed by Harlan F Weisman on 15 August 2023, trading 600,000 units of TFFP stock currently worth $150,000.

What does Tff Pharmaceuticals Inc do?

tff pharmaceuticals, inc. is a clinical-stage biopharma company focused on developing and commercializing drug products based on its patented thin film freezing (tff) technology. our patented thin film freezing (tff) platform makes it possible to turn more molecules into inhalable therapies. this novel technology provides high absorption and yield, uniform particle size, gentle process and endless possibilities. tff pharmaceuticals has two lead drug candidates: voriconazole inhalation powder and tac-lac inhalation powder. the company plans to add to this pipeline by collaborating with large pharmaceutical partners. the tff platform is protected by 42 patents issued or pending in the us and internationally.

Complete history of Mr Coleman stock trades at Tff Pharmaceuticals Inc

Tff Pharmaceuticals Inc executives and stock owners

Tff Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Glenn R. Mattes,
  Pres, CEO & Director
• Kirk Allen Coleman,
  CFO, Treasurer & Sec.
• Christopher Cano,
  COO & VP of Bus. Devel.
• Paul F. Manley,
  Head of Regulatory Affairs
• Dr. Anthony J. Hickey Ph.D.,
  Chief Scientific Officer
• Dr. Dale Christensen,
  Director of Clinical Devel.
• Dr. James Brian Windsor Ph.D.,
  Chief Science Officer & Director
• Dr. James Brian Windsor,
  Chief Science Officer & Director
• Malcolm Fairbairn,
  Director
• Zamaneh Mikhak,
  Chief Medical Officer
• Robert S Mills,
  Director
• Glenn R. Mattes,
  President and CEO
• James Brian Windsor,
  Chief Science Officer
• Aaron G.L. Fletcher,
  Director
• Randy H Thurman,
  Director
• Brandi Roberts,
  Director
• Stephen Rocamboli,
  Director
• Therapeutics, Inc. Lung,
  10% owner
• Michael A Patane,
  Director
• Catherine Chai Zon Lee,
  Director
• Christopher Cano,
  Chief Operating Officer
• Harlan F Weisman,
  President and CEO
• Kirk Allen Coleman,
  Chief Financial Officer
• Capital L P Double Black Di...,
  
• Thomas Braxton King,
  Director